Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33372859

about

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values.Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus.Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response.Small hepatocellular carcinomas and thrombocytopenia.Thrombocytosis and hepatocellular carcinoma.Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community.Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase.Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.Platelet-related phenotypic patterns in hepatocellular carcinoma patients.No sustained impact of intermittent extracorporeal liver support on thrombocyte time course in a randomized controlled albumin dialysis trial.Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.Favorable effect of thrombocytopenia on outcomes of liver transplantation for hepatocellular carcinoma.Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.Histological and clinical characteristics of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension.Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis.Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan Routine blood tests to predict liver fibrosis in chronic hepatitis C.Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1 Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian Patients.Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients.Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.Influencing factors of transient elastography in detecting liver stiffness.Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.Immune-Mediated Therapies for Liver Cancer.NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy.Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma.Hepatitis B awareness and education: a failing grade.

P2860

Q28074484-FFAA50C6-587A-4383-BBE4-B1F6CBE639A0 Q30853941-F1904A03-8959-42CB-819D-464B0A394E48 Q33388299-6BBDCB51-203C-4DAB-8C69-30CF60A2275D Q33401660-EBF8D9A4-1E14-4739-ADD7-2F631283D36B Q33402027-30BBAC92-3A84-4A98-A7E9-97F6543B0627 Q33403491-695C31D0-5B48-407A-98C2-190B3C7C649F Q33403504-DF57EB85-DCF0-40A0-A404-397676E3656F Q33405280-4874C4E8-CFAB-496E-A5BA-A894CA8651AB Q33405296-22D7AFD5-2381-4665-8840-A84BE6272C59 Q33410073-B2A5F8CB-A077-4638-8066-A3F983BA66A3 Q33410866-08CE84A1-F378-4097-AB64-4924E03F4E4A Q33416416-279AA17C-6A6D-429C-90A7-664BFE3E1E09 Q33417539-A36C6266-4264-4D10-B54A-11D8E45BB17C Q33427048-698D226B-1902-4768-9336-488559DE7E6A Q33429335-847549E3-AA33-4C27-A715-786DEBEDB9E5 Q33430833-35F2309C-2C8B-4614-9D77-DAF93C1D569E Q33660486-0C1D183D-3FB6-4B57-848E-02EF2855CF98 Q33843701-D9910E8E-E483-440A-9E32-40244494ACB1 Q33855761-3C93FFE2-A240-4152-9DD5-3B640DF9872A Q34123927-FF774E73-1DAA-4435-ADBA-F10C4A7565AC Q34365396-22F9630D-BAE0-4235-B3A1-52B5875A0100 Q34974963-65B3AA1A-0958-4948-ADBC-046D0884643F Q35776097-6CAB475C-1BD9-460B-8921-88916A10C999 Q36019476-2B6F3F21-1C8C-4314-AC66-FD33CAF12126 Q36143638-9E14DC3B-F317-46A1-8C1C-8263EF81D31F Q36194266-E526413A-D345-486C-9F93-33B9FF4E5FDC Q36724410-BDD226AC-4FFC-4AF4-9179-7345DD0A84E0 Q36929039-E66C9FEB-13D7-42A0-9DFC-2DC488221406 Q36962049-8201E5B0-A271-4DE5-A25E-01985C785A11 Q37099393-87482AE3-FA9E-4CA0-A92D-191D575B7022 Q37112127-B14BF7A0-17F6-4C37-919F-EA8314DF15C6 Q37279232-D22DCF38-8D83-4EF1-AFC6-1AAD6A802864 Q37288731-65173039-A424-4B54-9450-62B7382A245C Q37988322-6B68A003-4D69-4B07-8A56-319E0B662D60 Q39144327-B90F6D9D-5DDD-4C44-9004-5882AA4961AC Q39474147-8DF9E3D8-3E91-4F6B-BB92-55C2956CA09D Q39854779-EF94C2DC-8FA4-4140-ABDC-D84E307136E9 Q40985953-49192970-415C-4EB4-9A0D-D293C4516688 Q41561869-95107C43-EA50-4D50-894D-534B52684D7D Q42716192-118257DF-3CE0-4634-B6A1-A02899A6661C

P2860

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33372859

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@ast

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@en

type

label

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@ast

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@en

prefLabel

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@ast

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@en

P1433

Q33372859-EE7CD0E4-2003-4BFB-8240-9C73FDF0E1F1

P1476

Q33372859-117F3A80-6ADC-4C1A-BA5F-117226F603A8

P2093

Q33372859-0ED6ED4E-D1EF-4DFB-BE2A-7D0233607844

Q33372859-1EAF3F0B-21E1-4789-AE34-926FF77B784F

Q33372859-28F36948-6939-4170-BE3D-1571C25BC92C

Q33372859-3A7BAEC2-B38B-47FF-833A-9EB34D0A3C4D

Q33372859-632D7E0A-57FF-4545-B8D1-C1B39E80B310

Q33372859-73981FF9-555C-4D95-A1D4-FB987B5F2F63

Q33372859-8B23F90B-678D-40D9-8854-ADD9D0371DAB

Q33372859-9FF89DA6-5A23-4F42-B0EC-0BB10F051165

Q33372859-BF7E9050-9387-40CC-B29A-DFBCF1A93B9C

Q33372859-BFF772B8-A14A-417C-8DF3-9CFF234B176B

P304

Q33372859-061A33C8-D4F1-4E0E-8991-E6A383C4ABFD

P31

Q33372859-BF797BDB-28AC-42A2-9AEA-2F1A252B7489

P356

Q33372859-AED45EE0-C631-47B8-84E7-EADCCBB4A6B1

P407

Q33372859-CB224E96-DF3D-44C7-A20A-A1D52242B310

P433

Q33372859-5A80126F-5DD2-4A48-9AA1-9E89D1850362

P478

Q33372859-649B2EEA-19E1-49F7-ABD2-5E3194561764

P577

Q33372859-C041422D-5A0D-4F8D-9A3E-E188B42F31B3

P698

Q33372859-DC55E606-F345-43D6-AC30-A8D61DFB0750

P921

Q33372859-AD2760C7-B89F-4FCE-A42B-81CC47327EC1

Q33372859-C7B1B4F9-D4EE-4C4A-AD2C-D05EAEF450B0

P356

P1433

P1476

Thrombocytopenia as a surrogat ...... for hepatocellular carcinoma.

@en

P2093

Chao-Hung Hung

http://www.w3.org/2001/XMLSchema#string

Chi-Sin Changchien

http://www.w3.org/2001/XMLSchema#string

Chia-Cheng Chen

http://www.w3.org/2001/XMLSchema#string

Chien-Hung Chen

http://www.w3.org/2001/XMLSchema#string

Chuan-Mo Lee

http://www.w3.org/2001/XMLSchema#string

Hung-Da Tung

http://www.w3.org/2001/XMLSchema#string

Jing-Houng Wang

http://www.w3.org/2001/XMLSchema#string

Sheng-Nan Lu

http://www.w3.org/2001/XMLSchema#string

Shiann-Long Liu

http://www.w3.org/2001/XMLSchema#string

Tsung-Ming Chen

http://www.w3.org/2001/XMLSchema#string

P304

2212-2222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22242

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17019738

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

thrombocytopenia